Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · June 24, 2024

Outcomes of Treatment With Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

American Journal of Clinical Dermatology

 

Additional Info

American Journal of Clinical Dermatology
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
Am J Clin Dermatol 2024 May 01;25(3)485-496, JI Silverberg, MJ Gooderham, AS Paller, M Deleuran, CG Bunick, LFS Gold, D Hijnen, BM Calimlim, WJ Lee, HD Teixeira, X Hu, S Zhang, Y Yang, A Grada, AM Platt, D Thaçi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading